Sigma Planning Corp Moleculin Biotech, Inc. Transaction History

Sigma Planning Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$0.41 - $0.86 $2,050 - $4,300	-5,000 Reduced 29.41%	12,000 $10,000
Q2 2023 Aug 01, 2023	SELL	$0.54 - $0.95 $21,870 - $38,475	-40,500 Reduced 70.43%	17,000 $9,000
Q1 2022 Apr 20, 2022	BUY	$1.23 - $1.9 $17,835 - $27,550	14,500 Added 33.72%	57,500 $102,000
Q4 2021 Feb 02, 2022	BUY	$1.64 - $2.83 $70,520 - $121,690	43,000 New	43,000 $80,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $73.2M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.